🫀 La #SaludCardiovascular debe ser una prioridad para todos. Este es nuestro principal mensaje en esta #SemanaDelCorazón, en la que aprovechamos para concienciar sobre las #Miocardiopatías, enfermedades cardiovasculares menos conocidas, entre ellas la #MiocardiopatíaHipertrófica. 👉 La #MCH es una enfermedad cardíaca, a menudo hereditaria, que puede llegar a afectar a 1 de cada 500 adultos. Se trata de una patología crónica, debilitante y progresiva en la que los #pacientes presentan falta de aliento, mareos y cansancio, así como otras complicaciones más graves, como insuficiencia cardíaca, #arritmias #ictus e incluso la #muertesúbita. 🩺 La #HCM (por sus siglas en inglés) supone un gran desafío, ya que muchas personas no experimentan síntomas evidentes en las primeras etapas de la enfermedad. Esto dificulta su detección temprana, por lo que resulta esencial un enfoque integral mediante tratamientos más personalizados que aborden los diferentes subtipos de miocardiopatías y las necesidades específicas de los pacientes. 👥 Pero desde #BMSIberia no podemos pasar por alto la importancia del consejo #genético en este proceso. Proporcionar educación y apoyo antes y después de las pruebas genéticas, y ayudar a las familias a tomar decisiones informadas supone un proceso de acompañamiento que fortalece nuestro compromiso con quienes tienen #EnfermedadesCardiovasculares. 🔗 Conoce más de cerca las miocardiopatías con este artículo de Diariofarma 👇 https://lnkd.in/dg3wHsXT #UseHeart #DíaMundialdelCorazón #CardiomyopathiesMatter #Miocardiopatías #MiocardiopatíaHipertrófica #BMSIberia #BMSEspaña #BMSPortugal #BMSCommunity #BMSTransformingLives #WorkingTogetherforPatients #BMSTransformingPatientsLive
Publicación de Bristol Myers Squibb
Más publicaciones relevantes
-
Through our clinical research, we are progressing treatment approaches for patients with thalassemia, a genetic blood disorder with limited treatment options. Learn about our ongoing clinical trials for this condition.
Learn more about our clinical trials
Inicia sesión para ver o añadir un comentario.
-
Our extensive experience in autoimmune diseases and cell therapy drives our commitment to reshaping the treatment landscape for patients. This #LupusAwarenessMonth, Ashley Koegel shares how we’re building upon our legacy in #CARTCellTherapy and #immunology to drive cutting-edge research that has the potential to transform the treatment paradigm for patients with severe and progressive lupus. #DecodedByBMS
Bringing the science of cell therapy into autoimmune diseases
Bristol Myers Squibb en LinkedIn
Inicia sesión para ver o añadir un comentario.
-
Stroke is a leading cause of death and serious disability worldwide, which is why we’re pursuing transformational research for individuals who are at elevated risk. Our comprehensive Phase 3 Librexia program in collaboration with Johnson & Johnson Innovative Medicine aims to advance research for the prevention of stroke and help address the gap in unmet needs in thrombosis management. #StrokeMonth
Inicia sesión para ver o añadir un comentario.
-
Last year, we participated in a pilot program to recycle lab plastics, including multi-layer flexible bags and PPE, which promises to help us progress in our ongoing sustainability journey. As #EarthMonth closes, learn how we're setting our sights on a more sustainable world for our patients and communities—and our work still ahead: https://bit.ly/3Wjh2gk
Inicia sesión para ver o añadir un comentario.
-
From getting a behind-the-scenes look at our film production studio to experimenting with strawberries to uncover the structure of double helixes, this year’s Take Your Child to Work Day was an inspiring one for our future generation of leaders. Learn more about how we support working parents at every milestone as part of our commitment to fostering a culture of inclusion: https://bit.ly/3UAj3U6
Inicia sesión para ver o añadir un comentario.
-
We have been recognized by the Philadelphia Business Journal for our partnership with Drexel University enabling key STEM education initiatives to build the next generation of scientists who’ll transform patients’ lives through science. Through a grant from BMS, Drexel’s Program has successfully enrolled 91 students in Cell and Gene Therapy, Engineering, Analytics, Manufacturing & Science curriculum, and granted funding to 50 scholars from diverse communities to attend the Biomed Summer Academy with a focus on STEM education and biomedical research. In partnership with BMS, Drexel offered a co-op rotational program to work directly with BMS researchers and scientists. These efforts are just one way we’re invested in the future of STEM education. Learn more about our efforts: https://lnkd.in/eT3wMJM6 #CARTcelltherapy #STEM #partnersinphilanthropy Image credit: Drexel University
Inicia sesión para ver o añadir un comentario.
-
At every step of our environmental sustainability journey, we're searching for ways to minimize our packaging footprint, transition to more reusable and/or recyclable solutions, and advance energy efficiency. This #EarthDay, we're honored to share that we've received the ENERGY STAR Partner of the Year award, which recognizes our commitment to energy management and our ongoing efforts toward a #CleanEnergyFuture. Learn more about our progress to advance the health and well-being of our patients and the planet in our 2023 ESG Report: https://lnkd.in/ePxUhd_6
Inicia sesión para ver o añadir un comentario.
-
We are pleased to announce a worldwide capacity reservation and supply agreement with Cellares for the manufacture of CAR T cell therapies, giving us access to a next-generation fully automated, end-to-end cell therapy manufacturing platform. As part of the agreement, Cellares will optimize and automate select BMS CAR T cell therapies onto its manufacturing platform, the Cell Shuttle. We look forward to our continued work with Cellares and to the promise this agreement will bring for patients benefiting from CAR T therapies. https://bit.ly/446Wfyx
Inicia sesión para ver o añadir un comentario.
-
Acute myeloid #leukemia (AML) is one of the most common types of leukemia in adults, however, common symptoms make it difficult to diagnose. At BMS, with support from our partners, Know AML, Acute Leukemia Advocates Network and others, we work tirelessly towards our goal of broadening the treatment landscape and remain committed to identifying innovative treatments and working toward the potential for improved outcomes for every patient living with this difficult-to-treat blood cancer. As we approach AML Awareness Day, learn more about AML: https://bit.ly/3Uyb4qR
Inicia sesión para ver o añadir un comentario.
1.397.681 seguidores